Clinical trials: Teratogens
Neural Tube Defects, Congenital Abnormalities
Birth Outcomes In Eswatini After Transition To Dolutegravir-Based Treatment
The goal of this observational study is to assess the birth outcomes of HIV-positive women delivering in hospitals in Eswatini who are receiving dolutegravir (DTG) or other anti-retroviral (ARV) drug regimens.
- Conditions
- Neural Tube Defects, Congenital Abnormalities, Teratogens
- Trial name
- NCT05883761
- Where
- 5 sites in Eswatini
- Volunteers
- 50,075 people, healthy volunteers welcome
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
Chemical Teratogen Exposure, Contraception Behavior
EMR Referrals for Teratogen and Contraceptive Counseling for Category D or X Medication Users: RCT
Investigators propose a randomized controlled trial of women taking category D or X medications seen in family medicine, internal medicine or in the Coumadin Clinic.
- Conditions
- Chemical Teratogen Exposure, Contraception Behavior, Contraception
- Trial name
- NCT02293213
- Testing
- EMR Referral, CTIS Counseling, Baseline Questionnaire
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of California, San Diego
Mental Disorders, Contraception
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
There is currently limited research that addresses the unique medication safety and family planning needs among women of reproductive age with psychiatric conditions.
- Conditions
- Mental Disorders, Contraception, Chemical Teratogen Exposure
- Trial name
- MSRP (NCT02292056)
- Testing
- 1-on-1 counseling
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Teratogens, Abnormalities, Drug-Induced
Electronic Notification of Teratogenic Risks
This study will use a factorial design randomized controlled trial to (1)compare multi-faceted decision support (intervention) to streamlined clinical alerts (control) and (2) evaluate whether collecting information about women's…
- Conditions
- Teratogens, Abnormalities, Drug-Induced, Contraception
- Trial name
- PREVENT (NCT00766207)
- Testing
- Clinical decision support, stream-lined clinical alert
- Where
- 4 sites in United States
- Volunteers
- 2,593 people
- Sponsor
- University of Pittsburgh